Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic

PLoS One. 2012;7(10):e48187. doi: 10.1371/journal.pone.0048187. Epub 2012 Oct 31.

Abstract

Background: 2009 pandemic influenza A/H1N1 (A(H1N1)pdm09) was first detected in the United States in April 2009 and resulted in a global pandemic. We conducted a serologic survey to estimate the cumulative incidence of A(H1N1)pdm09 through the end of 2009 when pandemic activity had waned in the United States.

Methods: We conducted a pair of cross sectional serologic surveys before and after the spring/fall waves of the pandemic for evidence of seropositivity (titer ≥40) using the hemagglutination inhibition (HI) assay. We tested a baseline sample of 1,142 serum specimens from the 2007-2008 National Health and Nutrition Examination Survey (NHANES), and 2,759 serum specimens submitted for routine screening to clinical diagnostic laboratories from ten representative sites.

Results: The age-adjusted prevalence of seropositivity to A(H1N1)pdm09 by year-end 2009 was 36.9% (95%CI: 31.7-42.2%). After adjusting for baseline cross-reactive antibody, pandemic vaccination coverage and the sensitivity/specificity of the HI assay, we estimate that 20.2% (95%CI: 10.1-28.3%) of the population was infected with A(H1N1)pdm09 by December 2009, including 53.3% (95%CI: 39.0-67.1%) of children aged 5-17 years.

Conclusions: By December 2009, approximately one-fifth of the US population, or 61.9 million persons, may have been infected with A(H1N1)pdm09, including around half of school-aged children.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype / immunology*
  • Influenza, Human / blood
  • Influenza, Human / epidemiology
  • Influenza, Human / immunology*
  • Influenza, Human / prevention & control
  • Middle Aged
  • Pandemics*
  • Prevalence
  • Sensitivity and Specificity
  • Seroepidemiologic Studies
  • United States / epidemiology
  • Vaccination
  • Young Adult

Substances

  • Antibodies, Viral

Grants and funding

The authors have no support or funding to report.